This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
by Moumi Mondal
The women's health market is booming, with Hologic and Quest Diagnostics leading the charge. But which one stands out more for investors today?
Here's Why Fresenius (FMS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Fresenius (FMS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Fresenius (FMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Fresenius (FMS) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
by Nalak Das
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
New Strong Buy Stocks for May 9th
by Zacks Equity Research
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.
Best Value Stocks to Buy for May 9th
by Zacks Equity Research
BNTGY, SSUMY and FMS made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 9, 2025.
Best Income Stocks to Buy for May 9th
by Zacks Equity Research
SSUMY and FMS made it to the Zacks Rank #1 (Strong Buy) income stocks list on May 9, 2025.
FMS Stock Up as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Fresenius Medical's first-quarter results showcase a strong segmental performance, along with reiterating its 2025 outlook for revenue growth.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Watch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss?
by Debanjana Dey
MedTech companies' quarterly results are likely to reflect strength in customer demand. Let's see how FMS, MASI and CLOV are placed ahead of their earnings releases.
Should You Buy, Sell, or Hold FMS Stock Before Q1 Earnings?
by Zacks Equity Research
Fresenius Medical Care heads into the first quarter of 2025 with momentum from cost savings, innovation like the 5008X launch, and a steady recovery in U.S. treatment volumes.
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts. Shares rise in pre-market.
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains
by Zacks Equity Research
Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook
by Zacks Equity Research
CNMD reports solid first-quarter results, driven by improving sales across both segments.
GE HealthCare Q1 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's first-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
ECL Stock Up in Pre-Market Following Q1 Earnings Meet Estimates
by Zacks Equity Research
Ecolab's robust performance across the majority of its segments drives its first-quarter organic sales despite business challenges.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
by Zacks Equity Research
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
by Zacks Equity Research
AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.
Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
by Zacks Equity Research
ITGR tops first-quarter estimates with strong sales and EPS growth. Margins expand, driven by new products, acquisitions, and operational efficiency.
Here's Why You Should Add Veeva Stock to Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.